Recombinant FVIIa in the management of intracerebral haemorrhage in severe thrombocytopenia unresponsive to platelet‐enhancing treatment
- 27 April 2005
- journal article
- case report
- Published by Wiley in Transfusion Medicine
- Vol. 15 (2), 145-150
- https://doi.org/10.1111/j.0958-7578.2005.00564.x
Abstract
Intracranial haemorrhage (ICH) is a dramatic and potentially life-threatening presentation of children with thrombocytopenia. Management is limited to supportive care. Recent evidence suggests that ongoing bleeding following the initial ICH may result in greater neurological morbidity and mortality. Haemostatic agents, including recombinant factor VIIa (rFVIIa), a product licensed for use in patients with haemophilia and inhibitors, may be helpful in reducing bleeding in children with refractory thrombocytopenia. We present the case of a 16-year-old girl with severe refractory immune thrombocytopenia, who presented with a major ICH and responded to treatment that included rFVIIa and platelet transfusions. The dose of rFVIIa was empirically chosen and based on reported cases in the literature. The case highlights a number of issues regarding off-label use of rFVIIa and demonstrates the need to prospectively collect accurate information on the off-label use of this new potentially useful medication.Keywords
This publication has 24 references indexed in Scilit:
- Recombinant factor viia for refractive haemorrhage in autoimmune idiopathic thrombocytopenic purpuraBritish Journal of Haematology, 2003
- Recombinant activated factor VII for cerebral injury—induced coagulopathy in pediatric patientsJournal of Neurosurgery, 2003
- Effect of recombinant factor VIIa (Novoseven[reg ]) on thrombocytopenia-like conditions in vitroSeminars in Hematology, 2001
- Inhibitor Antibodies to Factor VIII and Factor IX: ManagementSeminars in Thrombosis and Hemostasis, 2000
- Clinical efficacy and recovery levels of recombinant FVIIa (NovoSeven) in the treatment of intracranial haemorrhage in severe neonatal FVII deficiencyHaemophilia, 2000
- Activated Recombinant Human Coagulation Factor VII Therapy for Intracranial Hemorrhage in Patients with Hemophilia A or B with InhibitorsPathophysiology of Haemostasis and Thrombosis, 1998
- Early Hemorrhage Growth in Patients With Intracerebral HemorrhageStroke, 1997
- Recombinant factor VIIa for intracranial haemorrhage in a Jehovahʼs Witness with severe haemophilia A and factor VIII inhibitorsBlood Coagulation & Fibrinolysis, 1993
- Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality.Stroke, 1993
- Death and functional outcome after spontaneous intracerebral hemorrhage. A prospective study of 166 cases using multivariate analysis.Stroke, 1991